Physician profile
Michael L Sher
NPI 1336149707
$16,844.16
in general payments reported to CMS, 2019-2025
31 companies · $1,915 in 2025
The $1,915 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,410 · 2020: $3,049 · 2021: $3,059 · 2022: $1,897 · 2023: $1,505 · 2024: $1,010 · 2025: $1,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,429.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,682.79 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $2,515.82 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,655.24 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $1,526.14 | 2019-2022 | |
| Abbvie INC. | $1,214.18 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,078.68 | 2019-2025 | Xifaxan, Relistor |
| Pfizer INC. | $902.28 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $879.31 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $631.07 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Alkermes, INC. | $583.94 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $443.83 | 2019-2020 | |
| Allergan, INC. | $357.08 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $355.79 | 2021-2025 | |
| Amarin Pharma, INC. | $279.31 | 2019-2020 | |
| Genentech USA, INC. | $260.33 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $230.01 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $229.46 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $220.01 | 2022 | |
| Esperion Therapeutics, INC. | $196.72 | 2021-2025 | Nexletol |
| Bausch Health US, LLC | $114.37 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $89.08 | 2022 | |
| Amgen INC. | $72.40 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $66.04 | 2019 | |
| Idorsia Pharmaceuticals US INC | $57.73 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $53.61 | 2019-2023 | |
| Exact Sciences Corporation | $44.36 | 2023-2025 | Cologuard Collection Kit |
| Topcon Healthcare Solutions, INC. | $29.82 | 2020 | |
| Eisai INC. | $26.39 | 2019 | |
| Ascensia Diabetes Care US INC. | $19.90 | 2020 | |
| Daiichi Sankyo INC. | $14.64 | 2020 | |
| Indivior INC. | $13.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.